IBSP and glioblastoma: This inherent heterogeneity poses significant challenges to the development of effective therapeutic strategies, as treatment approaches must account for various subpopulations of cancer cells with distinct properties and drug sensitivities.[126] In MPS, the researchers observed the molecular interactions between patient‐derived perivascular niches and GBM cells.[127] These interactions have been shown to regulate GBM migration, proliferation, and mesenchymal transition by upregulating the expression of vascular‐enriched integrin‐binding sialoprotein (IBSP).